Cardinal Health Stock - Analyst targets and consensus in focus

Cardinal Health stock sits near recent highs while Wall Street maintains a broadly positive view. A fresh look at ratings and price targets shows a moderate-buy consensus and single-digit upside potential from current levels.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 19:44 CET. Details in the imprint.

Cardinal Health (US14149Y1082) stock remains supported by a broadly constructive analyst view. Fresh data on Wall Street ratings and price targets highlight a moderate-buy consensus and an implied upside of around high-single digits from the current share price.

What the analysts are signaling

According to consensus data compiled by MarketBeat, Cardinal Health currently carries an average rating of "Moderate Buy" from 17 analysts, underpinned by a mix of buy and hold recommendations. The distribution shows ongoing confidence but not a uniformly bullish stance.

The same data set points to an average 12-month price target of about $246.93 per share, implying roughly 8.5% upside from a recent reference price near $227.63. The individual targets span from approximately $208 on the low end to $275 at the top.

Recent target moves and sentiment

One of the more recent moves in broker research came from Wells Fargo, which trimmed its target on Cardinal Health shares from $256.00 to $245.00 while maintaining an "overweight" stance, according to a recent MarketBeat summary of analyst actions. That adjustment slightly narrows the upside but keeps a positive rating.

Broader commentary from research houses still highlights Cardinal Health as a relative outperformer in the medical distribution and supplies space, with Zacks currently assigning the stock a Rank #2 (Buy) in its latest sector overview. The ranking reflects favorable earnings estimate trends compared with some healthcare peers.

Tuesday focus on ratings and consensus

With Wall Street expectations a key driver for large healthcare distributors, the moderate-buy consensus and clustered targets in the mid-$200s suggest that analysts see Cardinal Health as a relatively stable value and earnings story rather than a high-volatility growth name. Upside forecasts remain measured.

For retail investors, the spread between the lowest and highest targets - roughly $208 to $275 - underlines how differently firms model reimbursement, generic pricing and cost pressures in Cardinal Health’s core markets. Overall, the consensus implies room for gains but also acknowledges regulatory and margin risks.

How the company makes its money

Cardinal Health generates the bulk of its revenue by distributing pharmaceuticals and medical products to hospitals, pharmacies and other care providers across the United States and internationally. The company also offers supply-chain services and specialty solutions for areas like oncology and gastroenterology.

Where the stock trades today

The shares of Cardinal Health (US14149Y1082) trade on the New York Stock Exchange under the ticker CAH at around $227.63 as of 06/17/2026, 17:30 ET.

Key facts on Cardinal Health stock

• Company: Cardinal Health, Inc.
• ISIN: US14149Y1082
• WKN: 879312
• Ticker: CAH
• Venue: NYSE
• Price (as of 06/17/2026, 17:30 ET): 227.63 USD
• Market cap: 56,000,000,000 USD (as of 06/17/2026)
• Sector / Industry: Health Care / Health Care Providers & Services
• Index membership: Standard & Poor's 500 index
• Next earnings date: 08/15/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.